It is believed that with the development of iPSCs, midbrain organoids, endolysosomal models, genome editing, optogenetics, and other technologies, more complete technical support will be provided to explore the mechanism of GBA1-PD [190, 213, 217, 264–266]. This evidence concerns the gene GBA1 and Parkinson disease.